| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/07/2026 | ±3.3% | +2.8% | over-priced |
| 05/08/2026 | ±2.9% | +1.2% | over-priced |
| 02/27/2026 | ±5.1% | -3.9% | over-priced |
| 11/07/2025 | ±2.7% | +1.8% | over-priced |
| 08/08/2025 | ±2.6% | +0.8% | over-priced |
| 05/02/2025 | ±3.1% | +3.0% | over-priced |
| 11/01/2024 | ±2.0% | +0.2% | over-priced |
| 08/02/2024 | ±2.7% | -2.9% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.54 | $5.0B | $1.2B |
| Q1 FY2026 | $0.83 | $3.6B | $650M |
| Q4 FY2025 | — | $4.4B | $1.0B |
| Q3 FY2025 | $0.80 | $3.1B | $625M |
BX (BX) reports in 10 days, with the next report estimated for 11/06/2026. Across the last 8 reports, options priced an average ±3.0% earnings move while the stock actually moved 2.1% on average — the market has systematically over-priced BX's earnings risk. Fundamentals into the print: EPS up 57.1% year-over-year, revenue up 35.9%. QuantLogix's live 5-factor engine currently reads BX as a buy at 59/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →